Sep 13, 2017
Eyevensys Appoints Thierry Bordet Ph.D. as Pre-Clinical Director

Paris (France), 13th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first...

Sep 4, 2017
Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer

Paris (France), 4th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first...

May 9, 2017
Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases

Eyevensys announces today that it has successfully treated the first patient in a first-in-human phase I/II trial of its lead candidate EYS606...

Apr 20, 2017
Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development

Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that...

Apr 11, 2017
Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development

Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that...

Mar 21, 2017
Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman

Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that...

Sep 15, 2016
Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million

Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral technology that allows a safe local...

May 31, 2016
Eyevensys appoints Dr. Patricia Zilliox, an Experienced Ophthalmology Clinical Development Leader, to Board of Directors

Lead product, EYS606 for uveitis, to start first clinical study in 2016

Paris (France), 31th May 2016 –...

Feb 18, 2016
Eyevensys Receives Orphan Drug Designation in the European Union for EYS606 for the Non-Infectious Uveitis (NIU)

Paris, 18th February 2016 –
Eyevensys, an IND-stage biotechnology company developing non-viral gene therapies in the eye, announced...

Oct 16, 2015
Eyevensys Closes €7.5m Series A Financing Round

– Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral technology that allows a safe...

Aug 28, 2015
Eyevensys appoints Dr. Francesco Sinigaglia as Chairman of the Board

Paris (France), XX 2015 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral...

Mar 28, 2015
Eyevensys Appoints Raffy Kazandjian as CEO

Paris (France), March 28, 2015 – Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first...

Mar 25, 2013
Eyevensys appoints Dr Ivan Cohen-Tanugi as CEO

Dr Ivan Cohen-Tanugi, with over 20 years’ experience in the international pharmaceutical industry, will prepare Eyevensys to launch...

Jan 16, 2012
Eyevensys closes €1.6m Seed Funding to develop its EyeCET Platform

The EyeCET platform allows the creation of a bio therapeutic factory in the eye for the treatment of various eye diseases

...